

# MARKET REPORT



## World Congestive Heart Failure (CHF) Treatment Devices Market - Opportunities and Forecasts, 2015 - 2022

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# World Congestive Heart Failure (CHF) Treatment Devices Market - Opportunities and Forecasts, 2015 - 2022

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)1300 321501 or **Email:** [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com)

# World Congestive Heart Failure (CHF) Treatment Devices Market - Opportunities and Forecasts, 2015 - 2022

Congestive heart failure (CHF) is a physiological condition that has an adverse impact on the pumping efficiency of the cardiac muscles. It characterizes the accumulation of fluid around the heart leading to inefficient pumping. The onset of CHF is marked by the failure of the ventricles to pump sufficient volume of blood to the body organs. This eventually leads to deposition of fluid in the lungs, abdomen, liver, and lower body. CHF is treated by a number of devices that maintain heart rhythm, such as pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs). The world CHF treatment devices market was evaluated at \$10,127.2 million in 2015, and is estimated to reach \$14,823.3 million by 2022, with a CAGR of 5.5% over the forecast period. This is primarily attributed to the constantly changing lifestyle habits (such as unhealthy dietary habits, excessive alcohol consumption, smoking, obesity, and lack of physical activity) which make individuals more susceptible to arrhythmia and heart failure. In addition, a number of factors such as the large number of technological advancements in CHF treatment devices, increased adoption rate of these devices, and rising emphasis on early intervention and primary prevention of heart-related disorders are responsible for driving the market. Conversely, stringent government regulations for the approval of CHF treatment devices, high cost of, and high preference to drugs for CHF treatment are some of the factors restraining the market growth. The report segments the world CHF treatment devices market based on product type, namely, pacemakers, cardiac resynchronization therapy (CRT) devices, implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs). Pacemaker is further segmented into dual-chamber pacemakers and single-chamber pacemakers. CRT devices is segmented into two major types, namely, CRT-P and CRT-D. ICDs is further segmented into transvenous implantable cardioverter defibrillator (T-ICDs) and subcutaneous implantable cardioverter defibrillator (S-ICDs). VADs is also segmented into left ventricular assist device (LVAD), right ventricular assist device (RVAD), and biventricular assist device (BIVAD). ICDs was the highest revenue-generating segment in 2015, owing to the stressful hyperactive lifestyle, unhealthy food habits, and growing number of aging population. Based on geography, the market is divided into North America, Europe, Asia-Pacific, and LAMEA regions. The key players in this market adopted product development and product launch as their key strategies to keep pace with the changing demands of consumers. Furthermore, companies launched cost-effective and technologically efficient products to strengthen their market position. The report provides a comprehensive analysis of the key players operating in the world CHF treatment devices market, such as Abiomed, Inc., Berlin Heart GmbH, Biotronik SE & Co. KG, Boston Scientific Corporation, HeartWare International, Inc., Jarvik Heart, Inc., LivaNova PLC, Medtronic plc, ReliantHeart Inc., and St. Jude Medical, Inc. Key Benefits The study provides an in-depth analysis of the world CHF treatment devices market with current trends and future estimations to elucidate the imminent investment pockets in the market. The report provides a quantitative analysis from 2015 to 2022 that would enable the stakeholders to capitalize on prevailing market opportunities. Extensive analysis of the world CHF treatment devices market, by product, helps in understanding the various types of devices used for the treatment of CHF and other related cardiac conditions. Competitive intelligence highlights the business practices followed by leading market players across various geographic regions. SWOT analysis enables to study the internal environment of the leading companies for strategy formulation. CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET KEY SEGMENTS: Congestive Heart Failure (CHF) Treatment Devices Market, By Product Pacemakers, By Type Implantable Pacemakers External Pacemakers Cardiac Resynchronization Therapy (CRT), By Type Cardiac Resynchronization Therapy-Pacemakers (CRT-P) Cardiac Resynchronization Therapy-Defibrillators (CRT-D) Implantable Cardioverter Defibrillators (ICDs), By Type Transvenous Implantable Cardioverter Defibrillator (T-ICDs) Subcutaneous Implantable Cardioverter Defibrillator (S-ICDs) Ventricular Assist Devices (VADs), By Type Left Ventricular Assist Device (LVAD) Right Ventricular Assist Device (RVAD) Biventricular Assist Device (BIVAD) By Geography North America U.S. Canada Mexico Europe Germany U.K. France Rest of Europe Asia-Pacific Japan China India Rest of Asia-Pacific LAMEA Latin America Middle East Africa

## Additional Details

**Publisher :** Allied Market Research

**Reference :** LI 16663

**Number of Pages :** 135

**Report Format :** PDF

**Publisher Information :**



**Allied Market Research**  
Diligent Intelligence - Improved Growth

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Global Market Research and Corporate Data

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

# Table Of Contents for World Congestive Heart Failure (CHF) Treatment Devices Market - Opportunities and Forecasts, 2015 - 2022 [Report Updated: 05-05-2016]

## • CHAPTER 1 INTRODUCTION

- 1.1 Report description
- 1.2 Key benefits
- 1.3 Key market segments
- 1.4 Research methodology
  - 1.4.1 Secondary research
  - 1.4.2 Primary research
  - 1.5.1 Analyst tools and models

## CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 CXO perspective
- 2.2 Market beyond what to expect by 2027 (\$Million)
  - 2.2.1 Moderate growth scenario
  - 2.2.2 Rapid growth scenario
  - 2.2.3 Diminishing growth scenario

## CHAPTER 3 MARKET OVERVIEW

- 3.1 Market definition and scope
- 3.2 Key findings
  - 3.2.1 Top investment pockets
  - 3.2.2 Top winning strategies
- 3.3 Porters five forces analysis
  - 3.3.1 High competition and fragmented market moderates the power of the suppliers
  - 3.3.2 Scattered and large number of buyers moderates their bargaining power
  - 3.3.3 High capital investment moderates the threat of new entrants
  - 3.3.4 High intensity of rivalry
  - 3.3.5 Unavailability of substitutes lowers the threat of substitutes
- 3.4 Market share analysis, 2015
- 3.5 Market dynamics
  - 3.5.1 Drivers
    - 3.5.1.1 Growing incidences of congestive heart failures
    - 3.5.1.2 Technological advancements in CHF treatment devices
    - 3.5.1.3 Increasing patient awareness
    - 3.5.1.4 Presence of high-unmet medical needs
  - 3.5.2 Restraints
    - 3.5.2.1 Limited insurance coverage and high cost of the CHF treatment devices

3.5.2.2 unfavorable preference to pharmaceutical interventions (drugs) over CHF treatment devices

3.5.3 Opportunities

3.5.3.1 Lucrative opportunities in emerging economies

3.5.3.2 Development of new MRI-labeled devices

## CHAPTER 4 WORLD CHF TREATMENT DEVICES MARKET, BY PRODUCT

4.1 Pacemakers

4.1.1 Key market trends

4.1.2 Key growth factors and opportunities

4.1.3 Market size and forecast

4.1.4 Implantable Pacemakers

4.1.4.1 Market size and forecast

4.1.5 External Pacemakers

4.1.5.1 Market size and forecast

4.2 Cardiac resynchronization therapy (CRT)

4.2.1 Key market trends

4.2.2 Key growth factors and opportunities

4.2.3 Market size and forecast

4.2.4 CRT-P (CRT with pacemaker function)

4.2.4.1 Market size and forecasts

4.2.5 CRT-D (CRT with pacemaker and ICD function)

4.2.5.1 Market size and forecasts

4.3 Implantable cardioverter defibrillators (ICDs)

4.3.1 Key market trends

4.3.2 Key growth factors and opportunities

4.3.2.1 Market size and forecast

4.3.3 Transvenous implantable cardioverter defibrillator (T-ICDs)

4.3.3.1 Market size and forecasts

4.3.4 Subcutaneous implantable cardioverter defibrillator (S-ICDs)

4.3.4.1 Market size and forecasts

4.4 Ventricular Assist Devices (VADs)

4.4.1 Key market trends

4.4.2 Key growth factors and opportunities

4.4.3 Market size and forecast

4.4.4 Left Ventricular assist device (LVAD)

4.4.4.1 Market size and forecasts

4.4.5 Right ventricular assist device (RVAD)

4.4.5.1 Market size and forecasts

4.4.6 Biventricular Assist Device (BIVAD)

4.4.6.1 Market size and forecasts

## CHAPTER 5 WORLD CHF TREATMENT DEVICES MARKET, BY GEOGRAPHY, 2015-2022

5.1 Overview

5.1.1 Market size and forecast

5.2 North America

5.2.1 Key market trends

5.2.2 Key growth factors and opportunities

5.2.3 Market size and forecast

5.2.4 U.S.

5.2.4.1 Market size and forecast

5.2.5 Canada

5.2.5.1 Market size and forecast

5.2.6 Mexico

5.2.6.1 Market size and forecast

5.3 Europe

5.3.1 Key market trends

5.3.2 Key growth factors and opportunities

5.3.3 Market size and forecast

5.3.4 Germany

5.3.4.1 Market size and forecast

5.3.5 France

5.3.5.1 Market size and forecast

5.3.6 U.K.

5.3.6.1 Market size and forecast

5.3.7 Rest of Europe

5.3.7.1 Market size and forecast

5.4 Asia-Pacific

- 5.4.1 Key market trends
- 5.4.2 Key growth factors and opportunities
- 5.4.3 Market size and forecast
- 5.4.4 India

- 5.4.4.1 Market size and forecast

- 5.4.5 China

- 5.4.5.1 Market size and forecast

- 5.4.6 Japan

- 5.4.6.1 Market size and forecast

- 5.4.7 Rest of Asia-Pacific

- 5.4.7.1 Market size and forecast

- 5.5 LAMEA

- 5.5.1 Key market trends
- 5.5.2 Key growth factors and opportunities
- 5.5.3 Market size and forecast
- 5.5.4 Latin America

- 5.5.4.1 Market size and forecast

- 5.5.5 Middle East

- 5.5.5.1 Market size and forecast

- 5.5.6 Africa

- 5.5.6.1 Market size and forecast

## CHAPTER 6 COMPANY PROFILES

- 6.1 Abiomed, Inc.

- 6.1.1 Company overview
- 6.1.2 Operating business segments
- 6.1.3 Business performance
- 6.1.4 Key strategic moves & developments
- 6.1.5 SWOT analysis

- 6.2 Berlin Heart GmbH

- 6.2.1 Company overview
- 6.2.2 Operating business segments
- 6.2.3 Key strategic move & development
- 6.2.4 SWOT analysis

- 6.3 Biotronik SE & Co. KG

- 6.3.1 Company overview



- 6.3.2 Operating business segments
- 6.3.3 Key strategic moves & developments
- 6.3.4 SWOT analysis

#### 6.4 Boston Scientific Corporation

- 6.4.1 Company overview
- 6.4.2 Operating business segments
- 6.4.3 Business performance
- 6.4.4 Key strategic moves & developments
- 6.4.5 SWOT analysis

#### 6.5 HeartWare International, Inc.

- 6.5.1 Company overview
- 6.5.2 Operating business segments
- 6.5.3 Business performance
- 6.5.4 Key strategic moves & developments
- 6.5.5 SWOT analysis

#### 6.6 Jarvik Heart, Inc.

- 6.6.1 Company overview
- 6.6.2 Operating business segments
- 6.6.3 Key strategic moves & developments
- 6.6.4 SWOT analysis

#### 6.7 LivaNova PLC

- 6.7.1 Company overview
- 6.7.2 Operating business segments
- 6.7.3 Business performance
- 6.7.4 Key strategic moves & developments
- 6.7.5 SWOT analysis

#### 6.8 Medtronic plc

- 6.8.1 Company overview
- 6.8.2 Operating business segments
- 6.8.3 Business performance
- 6.8.4 Key strategic moves & developments
- 6.8.5 SWOT analysis

#### 6.9 ReliantHeart, Inc.

- 6.9.1 Company overview
- 6.9.2 Operating business segments
- 6.9.3 Key strategic moves & developments
- 6.9.4 SWOT analysis

#### 6.10 St. Jude Medical, Inc.

- 6.10.1 Company overview
- 6.10.2 Operating business segments
- 6.10.3 Business performance
- 6.10.4 Key strategic moves & developments

## 6.10.5 SWOT analysis

### List of Figures

- FIG. 1 WORLD CHF TREATMENT DEVICES MARKET, BY PRODUCTS, 2015 VS 2022, (\$MILLION)
- FIG. 2 CHF TREATMENT DEVICES MARKET. BY GEOGRAPHY, 2015
- FIG. 3 IMPACT ANALYSIS OF MODERATE GROWTH SCENARIO (2022-2027)
- FIG. 4 IMPACT ANALYSIS OF RAPID GROWTH SCENARIO (2022-2027)
- FIG. 5 IMPACT ANALYSIS OF DIMINISHING GROWTH SCENARIO (2020-2027)
- FIG. 6 TOP INVESTMENT POCKETS IN WORLD CHF TREATMENT DEVICES MARKET
- FIG. 7 TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (2014-2016)
- FIG. 8 TOP WINNING STRATEGIES: NATURE AND TYPE
- FIG. 9 PORTERS FIVE FORCES ANALYSIS
- FIG. 10 MARKET SHARE ANALYSIS, 2015
- FIG. 11 CATEGORIZATION OF AGEING POPULATION ON THE BASIS OF REGIONS (2013)
- FIG. 12 WORLD IMPLANTABLE PACEMAKERS MARKET, (2015-2022) (\$MILLION)
- FIG. 13 WORLD EXTERNAL PACEMAKERS MARKET, (2015-2022) (\$MILLION)
- FIG. 14 WORLD CRT-P MARKET, (2015-2022) (\$MILLION)
- FIG. 15 WORLD CRT-D MARKET, (2015-2022) (\$MILLION)
- FIG. 16 WORLD T-ICDS MARKET, (2015-2022) (\$MILLION)
- FIG. 17 WORLD S-ICDS MARKET, (2015-2022) (\$MILLION)
- FIG. 18 WORLD LVAD MARKET, (2015-2022) (\$MILLION)
- FIG. 19 WORLD RVAD MARKET, (2015-2022) (\$MILLION)
- FIG. 20 WORLD BIVAD MARKET, (2015-2022) (\$MILLION)
- FIG. 21 U.S. CHF TREATMENT DEVICES MARKET, (2015-2022) (\$MILLION)
- FIG. 22 CANADA CHF TREATMENT DEVICES MARKET, (2015-2022) (\$MILLION)
- FIG. 23 MEXICO CHF TREATMENT DEVICES MARKET, (2015-2022) (\$MILLION)
- FIG. 24 GERMANY CHF TREATMENT DEVICES MARKET, (2015-2022) (\$MILLION)
- FIG. 25 FRANCE CHF TREATMENT DEVICES MARKET, (2015-2022) (\$MILLION)
- FIG. 26 U.K. CHF TREATMENT DEVICES MARKET, (2015-2022) (\$MILLION)
- FIG. 27 REST OF EUROPE CHF TREATMENT DEVICES MARKET, (2015-2022) (\$MILLION)
- FIG. 28 INDIA CHF TREATMENT DEVICES MARKET, (2015-2022) (\$MILLION)
- FIG. 29 CHINA CHF TREATMENT DEVICES MARKET, (2015-2022) (\$MILLION)
- FIG. 30 JAPAN CHF TREATMENT DEVICES MARKET, (2015-2022) (\$MILLION)
- FIG. 31 REST OF ASIA-PACIFIC CHF TREATMENT DEVICES MARKET, (2015-2022) (\$MILLION)
- FIG. 32 LATIN AMERICA CHF TREATMENT DEVICES MARKET, (2015-2022) (\$MILLION)
- FIG. 33 MIDDLE EAST CHF TREATMENT DEVICES MARKET, (2015-2022) (\$MILLION)
- FIG. 34 AFRICA CHF TREATMENT DEVICES MARKET, (2015-2022) (\$MILLION)
- FIG. 35 ABIOMED: NET REVENUE, 2013-2015 (\$MILLION)
- FIG. 36 ABIOMED: SWOT ANALYSIS
- FIG. 37 BERLIN HEART: SWOT ANALYSIS
- FIG. 38 BIOTRONIK: SWOT ANALYSIS
- FIG. 39 BOSTON SCIENTIFIC CORPORATION: NET SALES, 2013-2015, (\$MILLION)
- FIG. 40 BOSTON SCIENTIFIC CORPORATION: REVENUE BY BUSINESS SEGMENT, 2015 (%)
- FIG. 41 BOSTON SCIENTIFIC CORPORATION: RHYTHM MANAGEMENT REVENUE BY SUB-SEGMENT, 2015 (%)
- FIG. 42 BOSTON SCIENTIFIC CORPORATION: REVENUE BY GEOGRAPHY, 2015 (%)
- FIG. 43 BOSTON SCIENTIFIC CORPORATION: SWOT ANALYSIS
- FIG. 44 HEARTWARE: NET REVENUE, 2013-2015 (\$MILLION)
- FIG. 45 HEARTWARE: REVENUE BY GEOGRAPHY, 2015 (%)
- FIG. 46 HEARTWARE - SWOT ANALYSIS
- FIG. 47 JARVIK HEART: SWOT ANALYSIS
- FIG. 48 LIVANOVA: NET SALES, 2013-2015 (\$MILLION)
- FIG. 49 LIVANOVA: REVENUE BY BUSINESS SEGMENTS, 2015 (%)
- FIG. 50 LIVANOVA: REVENUE BY GEOGRAPHY, 2015 (%)
- FIG. 51 LIVANOVA: REVENUE BY GEOGRAPHY, 2015 (%)
- FIG. 52 LIVANOVA: SWOT ANALYSIS

FIG. 53 MEDTRONIC: NET SALES, 2013-2015 (\$MILLION)  
 FIG. 54 MEDTRONIC: REVENUE BY SEGMENT, 2015 (%)  
 FIG. 55 MEDTRONIC: CARDIAC AND VASCULAR GROUP REVENUE BY SUB-SEGMENT, 2015 (%)  
 FIG. 56 MEDTRONIC: SWOT ANALYSIS  
 FIG. 57 RELIANTHEART: SWOT ANALYSIS  
 FIG. 58 ST. JUDE MEDICAL: NET SALES, 2013-2015 (\$MILLION)  
 FIG. 59 ST. JUDE MEDICAL: REVENUE BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)  
 FIG. 60 ST. JUDE MEDICAL: REVENUE BY GEOGRAPHY, 2015 (%)  
 FIG. 61 ST. JUDE MEDICAL: SWOT ANALYSIS

#### List of Tables

TABLE 1 WORLD CHF TREATMENT DEVICES MARKET, MODERATE GROWTH SCENARIO, VALUE, 2022-2027 (\$MILLION)  
 TABLE 2 WORLD CHF TREATMENT DEVICES MARKET VALUE, RAPID GROWTH SCENARIO, 2022-2027 (\$MILLION)  
 TABLE 3 WORLD CHF TREATMENT DEVICES MARKET VALUE, DIMINISHING GROWTH SCENARIO, 2022-2027 (\$MILLION)  
 TABLE 4 WORLD CHF TREATMENT DEVICES MARKET, BY PRODUCT TYPE, 2015-2022 (\$MILLION)  
 TABLE 5 WORLD PACEMAKERS MARKET, BY GEOGRAPHY, 2015-2022 (\$MILLION)  
 TABLE 6 WORLD PACEMAKERS MARKET, BY TYPE, 2015-2022 (\$MILLION)  
 TABLE 7 WORLD CRT MARKET, BY GEOGRAPHY, 2015-2022 (\$MILLION)  
 TABLE 8 WORLD CRT MARKET, BY TYPE, 2015-2022 (\$MILLION)  
 TABLE 9 WORLD ICDS MARKET, BY GEOGRAPHY, 2015-2022 (\$MILLION)  
 TABLE 10 WORLD ICDS MARKET, BY TYPE, 2015-2022 (\$MILLION)  
 TABLE 11 WORLD VADS MARKET, BY GEOGRAPHY, 2015-2022 (\$MILLION)  
 TABLE 12 WORLD VADS MARKET, BY TYPE, 2015-2022 (\$MILLION)  
 TABLE 13 CHF TREATMENT DEVICES MARKET, BY GEOGRAPHY, 2015-2022 (\$MILLION)  
 TABLE 14 NORTH AMERICA: CHF TREATMENT DEVICES MARKET, BY COUNTRY, 2015-2022 (\$MILLION)  
 TABLE 15 NORTH AMERICA: CHF TREATMENT DEVICES MARKET, BY TYPE, (2015-2022) (\$MILLION)  
 TABLE 16 EUROPE: CHF TREATMENT DEVICES MARKET, BY COUNTRY, 2015-2022 (\$MILLION)  
 TABLE 17 EUROPE: CHF TREATMENT DEVICES MARKET, BY TYPE, (2015-2022) (\$MILLION)  
 TABLE 18 ASIA-PACIFIC: CHF TREATMENT DEVICES MARKET, BY COUNTRY, 2015-2022 (\$MILLION)  
 TABLE 19 ASIA-PACIFIC: CHF TREATMENT DEVICES MARKET, BY TYPE, (2015-2022) (\$MILLION)  
 TABLE 20 LAMEA: CHF TREATMENT DEVICES MARKET, BY COUNTRY, 2015-2022 (\$MILLION)  
 TABLE 21 LAMEA: CHF TREATMENT DEVICES MARKET, BY TYPE, (2015-2022) (\$MILLION)  
 TABLE 22 ABIOMED: COMPANY SNAPSHOT  
 TABLE 23 BERLIN HEART: COMPANY SNAPSHOT  
 TABLE 24 BIOTRONIK: COMPANY SNAPSHOT  
 TABLE 25 BIOTRONIK: OPERATING SEGMENTS  
 TABLE 26 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT  
 TABLE 27 BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS  
 TABLE 28 HEARTWARE: COMPANY SNAPSHOT  
 TABLE 29 JARVIK HEART: COMPANY SNAPSHOT  
 TABLE 30 LIVANOVA: COMPANY SNAPSHOT  
 TABLE 31 LIVANOVA: OPERATING SEGMENTS  
 TABLE 32 MEDTRONIC: COMPANY SNAPSHOT  
 TABLE 33 MEDTRONIC: OPERATING SEGMENTS  
 TABLE 34 RELIANTHEART: COMPANY SNAPSHOT  
 TABLE 35 ST. JUDE MEDICAL: COMPANY SNAPSHOT

# How to Buy...

World Congestive Heart Failure (CHF) Treatment Devices Market - Opportunities and Forecasts, 2015 - 2022 [Report Updated: 05-05-2016]

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/103287>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com) or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$5370** | Single User Price
- \$5910** | Five User License Price
- \$7800** | Enterprise License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.